Clinical

Videos

The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.

Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

Articles

According to investigators on the CheckMate 9LA trial, these data support the use of nivolumab plus ipilimumab and 2 cycles of chemotherapy as a new first-line treatment for patients with advanced non–small cell lung cancer, regardless of PD-L1 expression or histology.

First-Line Nivolumab/Ipilimumab and 2 Chemo Cycles Provide Superior OS Vs Chemo Alone in Advanced NSCLC

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Salma Jabbour, MD, on AEs Observed With Pembrolizumab Plus Concurrent Chemoradiotherapy in Stage III NSCLC

The approval of cemiplimab in non–small cell lung cancer was supported by results from the phase 3 EMPOWER-Lung 1 trial that investigated its use as monotherapy in the first-line setting compared with platinum-doublet chemotherapy in patients with locally advanced or metastatic disease whose tumor cells expressed PD-L1.

FDA Approves Cemiplimab as First-Line Treatment for Advanced, High PD-L1 NSCLC

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey spoke about the possible implications of the KEYNOTE-799 study findings.

Salma Jabbour, MD, on the Impact of the Ongoing KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 Study

Amgen announced that their new drug application for sotorasib was granted priority review by the FDA to treat patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

FDA Grants Priority Review to Sotorasib to Treat Patients With KRAS G12C–Mutated NSCLC

Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality of life, according to results of a pivotal phase 3 trial. 


Adjuvant Osimertinib Does Not Adversely Affect Health-Related QOL for EGFR+ NSCLC

The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.

Non-Small Cell Lung Cancer (NSCLC) | Topics